Key Points
- SVP Kevin McCallion sold 18,580 shares on April 8 at an average price of $7.05 for proceeds of $130,989, leaving him with 44,925 shares (a 29.26% reduction); the sale was executed under a Rule 10b5-1 trading plan.
- Multiple insiders, including a director, sold stock this week for a combined ~64,000 shares (~$450k) — all via 10b5-1 plans — which could create near-term downward pressure or raise investor questions despite being pre‑arranged.
- Shares trade around $7.14 (up ~2.6%), market cap ~$267M, and analysts have a consensus Hold rating with an average price target of $12, after the company recently beat quarterly revenue and EPS estimates.
908 Devices Inc. (NASDAQ:MASS - Get Free Report) SVP Kevin Mccallion sold 18,580 shares of the business's stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $7.05, for a total transaction of $130,989.00. Following the sale, the senior vice president directly owned 44,925 shares of the company's stock, valued at $316,721.25. This represents a 29.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
908 Devices Trading Up 2.6%
Shares of MASS opened at $7.14 on Friday. The firm has a market capitalization of $266.89 million, a P/E ratio of 12.98 and a beta of 0.54. 908 Devices Inc. has a 12-month low of $3.79 and a 12-month high of $9.34. The firm has a fifty day moving average price of $6.47 and a 200-day moving average price of $6.67.
908 Devices (NASDAQ:MASS - Get Free Report) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The firm had revenue of $17.38 million during the quarter, compared to analyst estimates of $16.19 million. 908 Devices had a net margin of 34.68% and a negative return on equity of 14.99%. Analysts predict that 908 Devices Inc. will post -1.99 earnings per share for the current year.
Institutional Trading of 908 Devices
A number of hedge funds have recently added to or reduced their stakes in MASS. Farther Finance Advisors LLC purchased a new stake in 908 Devices in the third quarter worth about $28,000. Raymond James Financial Inc. purchased a new stake in 908 Devices in the second quarter worth about $48,000. Daiwa Securities Group Inc. purchased a new stake in 908 Devices in the second quarter worth about $61,000. PCM Encore LLC purchased a new stake in 908 Devices in the fourth quarter worth about $62,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in 908 Devices in the second quarter worth about $77,000. 88.06% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have recently issued reports on MASS. Wall Street Zen raised shares of 908 Devices from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, 908 Devices presently has a consensus rating of "Hold" and an average price target of $12.00.
Read Our Latest Stock Analysis on 908 Devices
Key 908 Devices News
Here are the key news stories impacting 908 Devices this week:
- Neutral Sentiment: SVP Kevin J. McCallion sold 18,580 shares on April 8 at an average $7.05 (proceeds $130,989). The sale was executed under a Rule 10b5‑1 plan and left him with 44,925 shares. Form 4
- Neutral Sentiment: SVP Kevin J. McCallion sold an additional 5,420 shares on April 9 at an average $7.03 (proceeds ~$38.1k), also under a 10b5‑1 plan. He still holds 44,925 shares. Form 4
- Neutral Sentiment: Director Christopher D. Brown sold 17,578 shares on April 10 at $7.07 (proceeds ~$124.3k), under a 10b5‑1 plan; he remains a large holder (~945,559 shares). Form 4
- Neutral Sentiment: Director Christopher D. Brown sold 7,392 shares on April 9 at $7.04 (proceeds ~$52.0k), and 15,030 shares on April 8 at $7.05 (proceeds ~$106.0k); all under a 10b5‑1 plan. Form 4
- Neutral Sentiment: Reported short interest shows 0 shares (as of April 10), implying no measurable short pressure; the short‑interest ratio is effectively 0.0 days based on average volume. Source data flagged anomalous/NaN changes.
- Negative Sentiment: Combined impact: insiders sold ~64,000 shares this week for roughly $450k in proceeds. Even though sales were via 10b5‑1 plans (which mutes informational content), the concentrated volume of insider selling can create near‑term downward pressure or raise investor questions about insider liquidity needs.
908 Devices Company Profile
(
Get Free Report)
908 Devices Inc (NASDAQ: MASS) is a developer and manufacturer of portable analytical instruments designed to deliver rapid chemical detection in field and laboratory environments. The company's core focus lies in miniaturizing high-performance mass spectrometry and ion mobility spectrometry technologies, enabling users to perform on-site analysis that traditionally required benchtop equipment.
Key products in 908 Devices' portfolio include the MX908, a handheld high-resolution mass spectrometer capable of detecting and identifying a broad range of chemicals and explosives; the M908 portable mass spectrometer for laboratory or mobile units; and the ZipChip capillary electrophoresis system for high-throughput, microfluidic separations.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
